Hemangioma Treatment Market By Treatment Type (Propranolol, Corticosteroids, Laser Therapy, Surgical Excision, Other Treatments); By Disease Type (Infantile Hemangioma, Congenital Hemangioma, Acquired Hemangioma); By End User (Hospitals, Specialty Clinics, Ambulatory Care Centers, Others); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Hemangioma Treatment Market Outlook: How Large Is the Market and What Is Driving Therapeutic Innovation? – (Updated On: 07-Sep-2026)

The Global Hemangioma Treatment Market was valued at USD 420 million in 2025 and is projected to reach USD 600 million by 2032, expanding at a CAGR of 5.23% during 2026–2032, according to Strategic Market Research.

 

Hemangiomas are common benign vascular tumors, particularly infantile hemangiomas (IH). Global evidence indicates that approximately 2.8%–5% of infants develop IH, while some historical studies report prevalence approaching 10% during the first year of life. In the United States, reported incidence is approximately 1.1%–2% of births, with higher occurrence associated with prematurity and low birth weight. Adult vascular lesions also contribute to the clinical landscape, with hepatic hemangiomas reported in about 2.5% of adults and spinal hemangiomas identified in up to 10%, often incidentally.

 

Most uncomplicated infantile hemangiomas gradually regress and require only observation, meaning the treatment market is concentrated around patients with lesions that threaten vision, breathing, feeding, cause ulceration, or create significant functional or cosmetic complications. Approximately 10% of patients require active medical intervention.

 

Beta-blockers, particularly oral propranolol and topical timolol, are the principal treatment options for active hemangiomas. Additional therapies include corticosteroids when beta-blockers are unsuitable, laser therapy for superficial lesions and ulceration, and surgery for selected large or function-threatening lesions. Sclerotherapy and embolization may also be used for complex vascular masses, supporting a diversified treatment landscape across pharmaceuticals, procedures, and specialist care.

 

Hemangioma Treatment Market Leading and Fastest-Growing Segments

By Treatment Type

• Leading Segment – Propranolol: Propranolol led the Hemangioma Treatment Market with a 44.0% share, representing USD 184.8 million in 2025. Its leadership is supported by its established first-line role for infantile hemangiomas requiring systemic therapy, strong clinical-guideline support, and availability of the FDA-approved pediatric formulation HEMANGEOL.

• Fastest-Growing Segment – Other Treatments: Other treatments are projected to record the fastest CAGR of 6.60% during 2026–2032. Growth is supported particularly by topical beta-blockers for superficial lesions and emerging treatment approaches such as ASN-001, alongside embolization, sclerotherapy, and multimodal procedures for patients who require alternatives to conventional systemic treatment.

 

By Disease Type

• Leading Segment – Infantile Hemangioma: Infantile hemangioma dominated with a 72.0% market share, equivalent to USD 302.4 million in 2025. Its position reflects the comparatively high clinical prevalence, clearly established treatment pathway, use of propranolol as first-line systemic therapy, and availability of pharmaceutical, topical, laser, and surgical options for clinically significant lesions.

• Fastest-Growing Segment – Acquired Hemangioma: Acquired hemangioma is projected to register the fastest CAGR of 5.40% during 2026–2032, narrowly exceeding infantile hemangioma. Its expansion is supported by wider use of vascular laser systems, dermatologic procedures, and local excision across heterogeneous vascular lesions that develop beyond infancy.

 

By End User

• Leading Segment – Hospitals: Hospitals led with a 46.0% share, representing USD 193.2 million in 2025. Their leadership reflects the concentration of complicated periocular, airway, hepatic, ulcerated, and function-threatening hemangiomas in multidisciplinary centers with access to pediatric dermatology, surgery, ophthalmology, ENT, and interventional care.

• Fastest-Growing Segment – Specialty Clinics: Specialty clinics are projected to expand at the fastest CAGR of 5.89% during 2026–2032. Their growth reflects the shift of suitable cases toward outpatient propranolol monitoring, topical therapy, pediatric dermatology follow-up, and laser-based management without requiring hospital admission.

 

By Region

• Leading Region – North America: North America led the Hemangioma Treatment Market with a 40.0% share, equivalent to USD 168.0 million in 2025. The region benefits from FDA-approved HEMANGEOL, established pediatric dermatology and vascular-anomaly networks, access to advanced laser systems, specialty-pharmacy distribution, and structured reimbursement pathways.

• Fastest-Growing Region – Asia Pacific: Asia Pacific is forecast to register the fastest CAGR of 6.83% during 2026–2032. Expansion is supported by improving pediatric dermatology capacity, broader recognition of high-risk hemangiomas, increasing access to beta-blocker treatment and vascular laser procedures, and strengthening specialist care infrastructure in markets such as Japan and other major Asian healthcare healthcare systems.

 

Treatment Innovation Across Propranolol, Laser Therapy, Surgery, and Emerging Modalities

Propranolol dominated the Hemangioma Treatment Market, accounting for 44.0% of the market share and generating USD 184.8 million in revenue in 2025. As the standard first-line oral therapy for problematic infantile hemangiomas, propranolol effectively reduces lesion size and prevents further growth. Belonging to the beta-blocker drug class, it is commonly administered as an oral liquid formulation, making it suitable for infants. The segment is expected to grow at a CAGR of 5.64% from 2026 to 2032.

Corticosteroids represented 18.0% of the market, equivalent to USD 75.6 million in 2025, and are forecast to expand at a CAGR of 3.15%. Their comparatively slower development reflects their repositioning from historical first-line systemic treatment to an alternative for patients with contraindications or inadequate response to propranolol. The AAP continues to recognize oral prednisolone or prednisone and selected intralesional corticosteroid therapy in appropriate patients, preserving a clinically defined but substantially narrower treatment role.

Laser therapy represented 17.0% of the hemangioma treatment market, valued at USD 71.4 million in 2025, and is expected to expand at a CAGR of 6.20%. This growth is driven by its effectiveness in managing hemangiomas through advanced light-based technology. Laser therapy uses specific wavelengths of light to precisely target abnormal blood vessels, reducing their size and appearance while minimizing damage to surrounding healthy skin. Its safety, accuracy, and favorable cosmetic outcomes contribute to increasing adoption among patients and healthcare providers.

Surgical excision held 12.0% of the market, representing USD 50.4 million in 2025, and is expected to expand at a CAGR of 4.10%. Pharmacological treatment has reduced the need for early excision, leaving surgery concentrated in residual deformity, persistent ulceration, large periocular lesions affecting vision, medically refractory disease, and selected congenital hemangiomas. NCI also identifies resection as an option for rare severe hepatic congenital hemangiomas when supportive or radiological treatment is insufficient.

Other treatments accounted for 9.0% of the market, representing approximately USD 37.8 million in 2025, and are anticipated to register the fastest treatment-type CAGR of 6.60% during the forecast period. This segment includes alternative and supportive therapies such as laser therapy, corticosteroids, surgical excision, and embolization, which are primarily utilized when first-line beta-blocker therapy is ineffective, contraindicated, or insufficient. These approaches help manage complex cases, address complications, and provide additional treatment options for patients requiring individualized care strategies.

 

Disease-Type Opportunities Driving Hemangioma Treatment Market Growth

Infantile hemangioma represented the largest market segment, accounting for 72.0% of the overall market share and reaching USD 302.4 million in 2025. This segment is projected to grow at a CAGR of 5.36% during the forecast period. Infantile hemangioma refers to a common benign vascular birthmark that influences treatment decisions, as most cases naturally regress without intervention, while complex or high-risk lesions require timely diagnosis and targeted therapies to prevent complications and improve patient outcomes.

Congenital hemangioma represented 18.0% of the overall market, valued at USD 75.6 million in 2025, and is expected to grow at a CAGR of 4.60% during the forecast period. Unlike infantile hemangiomas, congenital hemangiomas do not respond effectively to beta-blocker therapies, making observation the primary management approach. Regular monitoring is preferred to assess natural progression, as many cases demonstrate spontaneous regression or stabilization without the need for medical intervention or aggressive treatment.

Acquired hemangioma segment accounted for 10.0% of the overall market, valued at approximately USD 42.0 million in 2025, and is projected to expand at a CAGR of 5.40% during the forecast period. The growth is primarily driven by the increasing preference for surgical excision, which remains the standard treatment approach for acquired hemangiomas, including acquired elastotic and capillary hemangiomas. Since these lesions typically do not resolve spontaneously, surgical removal is often required to achieve effective clinical outcomes.

 

Care Delivery Hubs Transforming Hemangioma Treatment Access and Outcomes

Hospitals held 46.0% of the Hemangioma Treatment Market, representing USD 193.2 million in 2025, and are projected to expand at a CAGR of 4.80%. Their leading position reflects the concentration of complex periocular, airway, hepatic, ulcerated, syndromic, and function-threatening lesions in multidisciplinary pediatric centers. NCI identifies dermatology, pediatrics, ophthalmology, otolaryngology, surgery, and other specialties as important components of hemangioma management, while severe congenital lesions may also require radiological intervention or surgery.

Specialty clinics accounted for 31.0% of the market, equivalent to USD 130.2 million in 2025, and are expected to grow at a CAGR of 5.89%. Pediatric dermatology and vascular-anomaly clinics are particularly relevant because systemic propranolol can often be monitored longitudinally in outpatient care, while thin superficial lesions and residual vascular changes can be managed with topical therapy or lasers. Eton's 2026 HEMANGEOL relaunch introduced exclusive specialty-pharmacy distribution through Anovo and Eton Cares patient support, strengthening the link between specialist prescribers, therapy initiation, and pharmaceutical access.

Ambulatory care centers represented 15.0% of the market, or USD 63.0 million in 2025, and are projected to expand at a CAGR of 5.50%. Their role is strongest in laser-based and minor procedures that do not require the broader clinical resources of a tertiary pediatric hospital. Products such as Candela's Vbeam and Cutera's excel V support outpatient vascular treatment because their platforms can also be used across other dermatologic vascular indications, improving equipment utilization within specialist procedural practices.

Other end users accounted for 8.0% of the market, representing USD 33.6 million in 2025, and are forecast to grow at a CAGR of 4.50%. Community pediatric practices, primary-care settings, and referral networks contribute mainly through lesion identification, monitoring, and timely referral rather than complex intervention. This function is important because the AAP notes that the most rapid infantile hemangioma growth generally occurs between one and three months and recommends early specialist evaluation for potentially high-risk lesions.

 

Regional Growth Frontiers in the Hemangioma Treatment Market

North America held a dominant position in the Hemangioma Treatment Market, accounting for 40.0% of the global market share, valued at USD 168.0 million in 2025. The region is expected to witness steady expansion at a CAGR of 4.60%, supported by evolving clinical guidelines, increased adoption of early intervention approaches, advanced healthcare infrastructure, and strong institutional support. These factors are driving improvements in diagnosis, treatment accessibility, and the overall management of hemangioma cases across the region.

has evolved rapidly, driven by the widespread acceptance of oral beta-blockers as the gold standard of care, offering effective and safe therapeutic outcomes for patients. In 2025, Europe accounted for 28.0% of the global market, valued at USD 117.6 million. The regional market is projected to expand at a CAGR of 4.80%, supported by increasing disease awareness, improved healthcare infrastructure, early diagnosis, and growing access to advanced treatment options across European countries.

Asia Pacific represented 22.0% of the market, or USD 92.4 million in 2025, and is projected to record the fastest regional CAGR of 6.83%. Market development is supported by expanding pediatric dermatology capability, greater access to vascular-anomaly specialists, and wider availability of medical and procedural therapies. Japan provides a mature example: recently published Japanese clinical practice guidelines identify propranolol as the first choice for infantile hemangioma requiring treatment and state that oral Hemangiol is generally covered by National Health Insurance, while topical beta-blocker use remains outside national insurance coverage.

Latin America accounted for 6.0% of the market, representing USD 25.2 million in 2025, and is forecast to expand at a CAGR of 5.30%. Treatment activity remains concentrated in larger pediatric hospitals and dermatology centers where specialists can differentiate uncomplicated lesions suitable for observation from cases requiring beta-blockers, laser therapy, or surgery. Oral beta-blocker therapy offers a comparatively accessible pharmacological pathway, while higher-cost vascular laser and complex interventional procedures remain more concentrated in major metropolitan centers.

Middle East & Africa held 4.0% of the market, equivalent to USD 16.8 million in 2025, and is expected to grow at a CAGR of 5.00%. Market development is linked to the expansion of tertiary pediatric services, dermatology expertise, and access to vascular laser and interventional capabilities. Systemic medication can be delivered through a broader range of healthcare facilities, whereas complex airway, hepatic, periocular, and surgical cases remain concentrated in advanced referral centers.

 

Competitive Landscape and Leading Company Portfolios in the Hemangioma Treatment Market

Competition in the Hemangioma Treatment Market is divided between disease-specific pharmaceutical therapy and broader vascular-treatment technologies. Pharmaceutical differentiation centers on labeled indication, pediatric formulation, administration route, safety management, patient access, and pipeline expansion, while device companies compete through wavelength selection, treatment precision, cooling systems, lesion coverage, and usefulness across multiple vascular indications. The emergence of a potentially approvable topical beta-blocker also introduces competition between inexpensive off-label therapy and a purpose-developed pediatric formulation.

Eton Pharmaceuticals

Eton has become the central U.S. pharmaceutical participant in infantile hemangioma following its February 2026 acquisition of U.S. rights to HEMANGEOL from Pierre Fabre and the May 2026 commercial relaunch. HEMANGEOL is FDA approved for proliferating infantile hemangioma requiring systemic therapy. Eton's portfolio also includes investigational ASN-001, a topical timolol gel intended for proliferating superficial infantile hemangiomas, giving the company a potential future portfolio spanning systemic and topical treatment.

Relevant portfolio: HEMANGEOL and ASN-001.

Pierre Fabre Medicament

Pierre Fabre remains relevant through Hemangiol, the propranolol oral solution authorized in the European Union for proliferating infantile haemangioma requiring systemic therapy. Although U.S. rights transferred to Eton in 2026, Pierre Fabre remains the EU marketing authorization holder and receives an 8% royalty on U.S. net sales during the applicable HEMANGEOL patent-protected period.

Relevant portfolio: Hemangiol propranolol oral solution.

Auson Pharmaceuticals

Auson's principal relevance is ASN-001, the topical timolol gel licensed to Eton for U.S. development. Auson previously completed a three-arm Phase II/III study involving 168 patients. The candidate is intended for proliferating superficial infantile hemangiomas and could provide a purpose-developed topical option for patients currently managed with off-label ophthalmic timolol products if future regulatory development succeeds.

Relevant portfolio: ASN-001 topical timolol gel.

Candela

Candela competes in the procedural segment through the Vbeam family of 595 nm pulsed-dye lasers. In June 2023, the Vbeam platform received expanded FDA 510(k) clearance covering pediatric patients from birth through 21 years for infantile and congenital hemangiomas. The technology targets vascular structures with 595 nm laser energy and incorporates dynamic epidermal cooling, positioning the platform for specialist treatment of selected superficial and residual vascular lesions.

Relevant portfolio: Vbeam Prima and Vbeam Perfecta pulsed-dye laser systems.

Cutera

Cutera participates through its vascular laser portfolio, including excel V and excel V+. These systems use 532 nm and 1064 nm wavelengths to coagulate benign vascular lesions at different tissue depths, with hemangiomas included among their indicated vascular applications. Their broader use across vascular dermatology allows practices to utilize the same capital equipment for hemangiomas alongside angiomas, telangiectasia, port-wine stains, and other lesions.

Relevant portfolio: excel V and excel V+ vascular laser platforms.

 

Analyst Commentary: Precision Topical Therapies and AI-Enabled Care Redefine Hemangioma Treatment

The hemangioma treatment market is likely to see its most meaningful breakthrough from topical beta-blocker innovation rather than another systemic drug. ASN-001, a purpose-developed topical timolol gel for superficial infantile hemangiomas, has the clearest near-term potential to create a new commercial treatment category. If successfully approved, it could fill the gap between observation and oral propranolol, particularly for small superficial lesions currently managed with off-label topical timolol.

Despite pipeline activity, oral propranolol is unlikely to lose its position as the systemic standard of care through 2032. Its established efficacy, guideline support, pediatric formulation, and physician familiarity create a high barrier for replacement. New therapies are therefore more likely to complement propranolol by targeting narrower patient groups rather than displace it.

Among emerging options, atenolol may gain selective use where tolerability is a concern, while sirolimus and other mTOR-pathway therapies could become important for refractory, complex, or high-risk vascular lesions. These precision therapies are unlikely to generate large patient volumes but could command greater clinical value in difficult-to-treat cases.

On the technology side, AI-based image analysis and teledermatology may become major market enablers by identifying high-risk infantile hemangiomas earlier and improving referral speed during the critical early-growth period. This could expand the pool of patients receiving timely treatment.

Laser therapy will also evolve toward multimodal treatment, combining pulsed-dye or deeper vascular lasers with beta-blockers for residual, ulcerated, or superficial lesions. Overall, the market is shifting from broad treatment approaches toward lesion-specific, outpatient, and precision-managed care, with topical therapy, AI-enabled triage, and combination treatment likely to drive the strongest innovation through 2032.

 

Hemangioma Treatment Market Assessment Methodology

The Hemangioma Treatment Market assessment used a secondary-research-led, top-down and bottom-up triangulation framework. Strategic Market Research was used as the baseline source for the 2025 global market value of USD 420 million, 2032 forecast of USD 600 million, 5.23% CAGR, and reported treatment-type, disease-type, end-user, and regional splits.

Market sizing was cross-checked by reconciling each segment’s 2025 revenue with the global market total and independently testing the forecast using the standard CAGR formula. The supplied treatment-type, disease-type, end-user, and regional revenues each reconcile to the USD 420 million 2025 total, while growth from USD 420 million in 2025 to USD 600 million in 2032 produces an implied CAGR of approximately 5.23%. Regional estimates were evaluated against infantile-hemangioma incidence and prevalence, treatment eligibility, specialist availability, beta-blocker utilization, vascular-laser access, pediatric dermatology infrastructure, pharmaceutical availability, reimbursement, and concentration of complex cases in tertiary vascular-anomaly centers.

Epidemiology and treatment-pool assumptions were benchmarked primarily against peer-reviewed systematic reviews and clinical literature indexed in PubMed. A large systematic review and meta-analysis covering 55 studies estimated the overall prevalence of infantile hemangioma at approximately 2.8%, while contemporary clinical literature generally places prevalence within a broader 3%–10% range depending on the population studied. Importantly, published clinical evidence indicates that only about 10% of infantile hemangiomas require active treatment, because most lesions undergo spontaneous involution. This distinction was incorporated when translating epidemiology into addressable treatment demand rather than equating total disease prevalence with treated patients. Adult hepatic, spinal, and other incidentally detected hemangiomas were treated primarily as contextual epidemiological indicators rather than being converted directly into pharmaceutical demand.

Treatment-pathway, regulatory, and product analysis relied on FDA information, the European Medicines Agency, National Cancer Institute treatment resources, American Academy of Pediatrics guidance, ClinicalTrials.gov, and official manufacturer disclosures. FDA information was used to validate HEMANGEOL as propranolol oral solution for proliferating infantile hemangioma requiring systemic therapy, while AAP guidance supported propranolol's first-line position for cases requiring systemic treatment. EMA records were used to validate Hemangiol's European authorization and current product status. NCI vascular-tumor resources supported assessment of topical beta-blockers, corticosteroids, laser therapy, surgery, embolization, and management differences between infantile and congenital hemangiomas.

Pipeline and therapeutic-innovation analysis focused on topical beta-blocker development and procedure-based technologies. ClinicalTrials.gov was used to verify the completed 168-patient Phase II/III study of timolol maleate gel ASN-001 for proliferating superficial infantile hemangioma, including study design, treatment duration, endpoints, and development status. Recent Eton Pharmaceuticals disclosures were used to validate the company's 2026 HEMANGEOL transition and relaunch and its acquisition of rights to ASN-001, including plans for additional development toward a potential NDA submission. Device-company regulatory and technical materials were used to assess vascular-laser platforms, including Candela's Vbeam pulsed-dye laser clearance for pediatric infantile and congenital hemangiomas.

Competitive analysis compared Eton Pharmaceuticals, Pierre Fabre Medicament, Auson Pharmaceuticals, Candela, Cutera, and other relevant participants by labeled indication, treatment modality, route of administration, pediatric formulation, clinical-development stage, regulatory status, lesion applicability, safety and monitoring requirements, specialist adoption, distribution strategy, and commercialization readiness. Pharmaceutical competition was evaluated separately from laser and procedural competition because the two groups address different stages and forms of hemangioma care. Recent company transactions and portfolio changes were checked against primary company disclosures to avoid attributing outdated U.S. commercialization responsibilities; Eton acquired U.S. rights to HEMANGEOL on February 27, 2026 and commercially relaunched the product on May 1, 2026.

Final estimates were triangulated across market-research benchmarks, epidemiological evidence, treatment eligibility, regulatory databases, clinical guidelines, trial registries, product approvals, regional treatment accessibility, and company disclosures. Greater analytical weight was assigned to government and regulatory sources, ClinicalTrials.gov, peer-reviewed literature, professional clinical guidance, and recent primary company materials, while market-research estimates were primarily used as the quantitative baseline and for segment-level benchmarking.

 

Hemangioma Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 420 Million
Revenue Forecast in 2032	USD 600 Million
Overall Growth Rate	CAGR of 5.23% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million
Segmentation	By Treatment Type, By Disease Type, By End User, and By Geography
By Treatment Type	Propranolol; Corticosteroids; Laser Therapy; Surgical Excision; Other Treatments
By Disease Type	Infantile Hemangioma; Congenital Hemangioma; Acquired Hemangioma
By End User	Hospitals; Specialty Clinics; Ambulatory Care Centers; Others
By Geography	North America; Europe; Asia Pacific; Latin America; Middle East & Africa
By Region	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Country Scope	U.S., Canada, U.K., Germany, France, Italy, Spain, China, Japan, India, South Korea, Brazil, Mexico, Saudi Arabia, U.A.E., South Africa
Market Drivers	Improving pediatric dermatology capacity, broader recognition of high-risk hemangiomas, increasing access to beta-blocker treatment and vascular laser procedures, and strengthening specialist care infrastructure
Customization Option	Available upon request